Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

v3.22.2.2
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS    
Financial Designation, Predecessor and Successor [Fixed List] Successor Predecessor
Net Loss $ (60,790,254) $ (24,650,712)
Adjustments to Reconcile Net Loss to Net Cash Used in Operating Activities:    
Depreciation Expense 590,549 332,548
Amortization of Intangibles 21,161,282  
Stock-Based Compensation 11,711,428 460,515
Amortization of Discount from Issuance of Debt   310,653
Mark-to-Market Adjustment of Stock Warrants 5,861,276 9,537,996
Amortization of Debt Origination Fees   171,936
Premium Deficiency Reserve (1,324,513) 2,000,000
Non-Cash Interest Expense 90,824  
Changes in Assets and Liabilities:    
Accounts Receivable 805,178 (46,822)
Health Plan Receivables / Premiums (44,336,698) (8,235,713)
Other Current Assets 215,542 (5,931)
Net Change in ROU Assets and Liabilities 58,423 9,014
Accounts Payable 4,018,630 85,555
Accrued Payroll 1,381,843 710,148
Accrued Interest 1,240,508 874,850
Health Plan Payables / Premiums (3,908,681) 1,988,897
Claims Payable 35,449,628 3,335,346
Net Cash used in Operating Activities (27,775,035) (13,121,720)
Cash Flows from Investing activities    
Purchase of Property and Equipment (877,165) (656,177)
Increase in Notes Receivable, Net (272,190) (73,495)
Net Cash used in Investing Activities (1,149,355) (729,672)
Cash Flows from Financing activities    
Repayment of Short-Term and Long-Term Debt (1,207,439) (22,224)
Net Cash used in Financing Activities (1,207,439) (22,224)
Net Change in Cash and Restricted Cash (30,131,829) (13,873,616)
Cash and Restricted Cash, Beginning of Period 140,833,872 39,902,947
Cash and Restricted Cash, End of Period $ 110,702,043 $ 26,029,331